Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.90 |
| ▸ | MAPT | P10636 | 2/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046163 | 0.96 | SMN1; SMN2 (0.84) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3059631 | 0.90 | ALDH1A1 (0.76) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3049631 | 0.88 | SMN1; SMN2 (0.79) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3049551 | 0.87 | NPC1 (0.78) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3048252 | 0.86 | EPHX1 (0.70) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3050539 | 0.86 | ALDH1A1 (0.70) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3046207 | 0.86 | SMN1; SMN2 (0.84) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3062637 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL3055302 | 0.86 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTALDH1A1NPC1HPGD | |
| SCHEMBL8363018 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2MAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200977-B1 | F1F0-ATPASE INHIBITORS AND RELATED METHODS | UNIV MICHIGAN (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8324258-B2 | F1F0-ATPase inhibitors and related methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100222400-A1 | F1F0-ATPase Inhibitors and Related Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222400-A1 | F1F0-ATPase Inhibitors and Related Methods | ATP5F1A, ATP5F1B, ATP5F1D | SMN1; SMN2 2992/4885MAPT 2714/4885ALDH1A1 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.